Table 2.
Relationship of serum predictor markers to TSPO VT
| Clinical Group | Region | Predictor markera | Contribution to variance (Adjusted R2 × 100%) | P-value |
|---|---|---|---|---|
| MDE (n = 20) | Prefrontal Cortex TSPO VT | ln(PGE2/CRP) | 33.0 | 0.0048 |
| ln(PGF2α/CRP)b | 35.0 | 0.0093 | ||
| ln(TNFα/CRP) | 36.2 | 0.0030 | ||
| TRD (n = 56) | Prefrontal Cortex TSPO VT | ln(PGE2/CRP) | 10.8 | 0.0076 |
| ln(PGF2α/CRP) | 2.6 | 0.12 | ||
| ln(TNFα/CRP) | 14.0 | 0.0026 | ||
| OCD (n = 20) | Dorsal Caudate TSPO VT | ln(PGE2/CRP) | 24.1 | 0.016 |
| ln(PGF2α/CRP) | 56.3 | <0.0001 | ||
| ln(TNFα/CRP) | 35.1 | 0.0035 |
aLinear regression with genotyped adjusted TSPO VT as dependent variable with predictor listed as independent
bPGF2α data missing from 4 medication free MDE subjects
CRP c-reactive protein, MDE major depressive episode, n number, OCD obsessive compulsive disorder, PGE2 prostaglandin E2, PGF2α prostaglandin F2 alpha, TNFα tumor necrosis factor alpha, TRD treatment resistant depression, TSPO VT translocator protein distribution volume